Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com
Neoadjuvant Chemotherapy Makes Organ-Sparing Surgery More Accessible for Patients With Rectal Cancer
October 11th 2022Neoadjuvant chemotherapy allowed 79% of patients with early-stage I/IIA rectal cancer to pursue organ-sparing excision surgery, potentially preserving their quality of life and bowel function.
Oral SERD Elacestrant Shows Significant PFS Improvement in ER+/HER2– Advanced Breast Cancer
October 6th 2022Elacestrant, an oral selective estrogen receptor degrader, may hold the potential to replace intramuscular fulvestrant injections for patients with endocrine receptor–positive, HER2-negative breast cancer.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for Patients
September 28th 2022Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Nurse-Led Research Links Saturate Fatty Acids to Improved Immunotherapy Responses in NSCLC
September 23rd 2022Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.
Oncology Nurses Must Understand the Later Effects of HSCT To Provide Adequate Survivorship Care
September 21st 2022In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.
Are Hearing Tests Necessary For Adult Cancer Survivors?
September 15th 2022In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.
HRQOL Analysis of KEYNOTE-522 Supports Pembrolizumab Treatment for Triple-Negative Breast Cancer
September 12th 2022Patients with triple-negative breast cancer who received pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores compared with patients who received placebo.